Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its initial public offering (IPO) of 46,620,000 shares in Hong Kong. The company filed its prospectus with the Hong Kong Stock Exchange in November of last year, with CICC and CCB International serving as co – sponsors.
Focus on miRNA Test Kits
Mirxes specializes in blood – based miRNA test kit products, with a portfolio that includes commercialized products GASTROClear, LungClear, and Fortitude. The company also has six pre – clinical candidate products in its pipeline. GASTROClear, a blood – based miRNA detection group consisting of 12 miRNA biomarkers for gastric cancer screening, received approval in Singapore in May 2019. This product highlights Mirxes’ innovative approach to early cancer detection through non – invasive testing methods.
IPO and Future Prospects
The IPO filing in Hong Kong represents a significant step forward for Mirxes as it seeks to expand its market presence and accelerate the development of its RNA – based diagnostic solutions. The funds raised through the IPO are expected to be utilized for further research and development, as well as for the commercialization of its pre – clinical candidate products. With a strong focus on miRNA technology and a proven track record of product approvals, Mirxes is well – positioned to capitalize on the growing demand for advanced diagnostic tools in the global healthcare market.-Fineline Info & Tech
Leave a Reply